← Who reports today · Health Care
How Bristol Myers Squibb (BMY) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · reported 07/30/2026
Bristol Myers Squibb — Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. · Wikipedia
More about the company
The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. Market share (US pharma & biotech): ≈7% by TTM revenue.
Key growth driver: Growth Portfolio — the fastest-growing revenue line: $7,560, +15% y/y. · by the Q2 2026 report
How does Bristol Myers Squibb make money?
Bristol Myers Squibb brought in $13.0 billion of revenue in Q2 2026, up 5.7% year over year. The largest source was Growth Portfolio: $7.56 billion, or 58% of the total, followed by Legacy Portfolio ($5.42B, 42%). Net income for the quarter was $3.32 billion, up 153% year over year.
Revenue by source, Q2 2026
- Growth Portfolio$7.56B · 58% · +15%
- Legacy Portfolio$5.42B · 42% · −4%
Shares of $13.0B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is BMY’s next earnings date?
Thursday, October 29, 2026confirmed · before market open
Bristol Myers Squibb (BMY) is scheduled to report results for the quarter ending Sep 2026 on Oct 29, 2026. Consensus EPS forecast: $1.68 (9 analysts), vs $1.63 in the same quarter last year.
What time does BMY report? Usually before market open: the last 4 results releases reached the SEC at 7:05 am, 7:01 am, 7:07 am, 7:09 am ET.
Last report: Jul 30, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →
All figures in $M.
Revenue
$12,973
+5.7%
Gross profit
$9,247
+3.4%
71.3% margin
Operating income
$4,025
+156%
Net income
$3,317
+153%
EPS $1.62
Verdict: a strong quarter — Growth Portfolio (+15%) and a swing to net Other Income offset Legacy Portfolio erosion and higher R&D, driving GAAP net income up 153% and prompting a raised full-year outlook.
Raised FY2026 revenue guidance to ~$49.0-50.0B; non-GAAP EPS guidance raised to $6.75-$7.00; FY opex now ~$16.5B.
Source and notation
* marks non-cash / ≈ estimated. Source: Bristol Myers Squibb press release / 10-Q (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
BMY earnings history: past report dates
| Jul 30, 2026 Thu | 7:05 ambefore market open | Jun 30, 2026 | $13.0B+6% y/y | $1.62+153% y/y |
| Apr 30, 2026 Thu | 7:01 ambefore market open | Mar 31, 2026 | $11.5B+3% y/y | $1.31+9% y/y |
| Feb 5, 2026 Thu | 7:07 ambefore market open | Dec 31, 2025 | ≈$12.5B+1% y/y | ≈$0.54+980% y/y |
| Oct 30, 2025 Thu | 7:09 ambefore market open | Sep 30, 2025 | $12.2B+3% y/y | $1.08+80% y/y |
| Jul 31, 2025 Thu | 7:06 ambefore market open | Jun 30, 2025 | $12.3B+1% y/y | $0.64−23% y/y |
| Apr 24, 2025 Thu | 7:11 ambefore market open | Mar 31, 2025 | $11.2B−6% y/y | $1.20 |
| Feb 6, 2025 Thu | 7:46 ambefore market open | Dec 31, 2024 | ≈$12.3B+8% y/y | ≈$0.05−94% y/y |
| Oct 31, 2024 Thu | 7:52 ambefore market open | Sep 30, 2024 | $11.9B+8% y/y | $0.60−35% y/y |
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Bristol Myers Squibb: 5-year financials
| 2025 | 48,194 | 7,054 | 12,845 | 5,045 |
| 2024 | 48,300 | −8,948 | 13,942 | 4,863 |
| 2023 | 45,006 | 8,025 | 12,651 | 4,744 |
| 2022 | 46,159 | 6,327 | 11,948 | 4,634 |
| 2021 | 46,385 | 6,994 | 15,234 | 4,396 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP).
How we calculate
Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
Corporate governance
1.5/2mostly good
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
More
- Feb 202610-K FY2025: in September 2025 the parties reached a settlement of the Celgene shareholder class action (purchasers from Apr 2017 to Apr 2018); the court granted preliminary approval in Dec 2025. sec.gov ↗
- May 2026The court granted final approval to a $239M settlement of the suit by former Celgene shareholders over overstated prospects for Otezla and Zeposia. news.bloomberglaw.com ↗
- Feb 2026Dividend per share $1.84 (2020) → $2.49 (2025), raised every year; diluted shares −9.7% over 5 years. data.sec.gov ↗
Scoring: 2.0 −0.5 (criterion 9: $239M settlement of the former Celgene shareholders' suit, approved by the court in May 2026) = 1.5
- Share classes
- Single class of common stock; the Celgene CVR is a separate non-voting security.
- Dilution
- Diluted shares 2,258M (2020) → 2,039M (2025), −9.7%; SBC 1.1% of revenue; the all-stock Celgene acquisition was in 2019, outside the 5-year window.
- Disclosure
- Full reporting.
- Dividends
- Dividend raised every year: $1.84 (2020) → $2.49 (2025); buybacks of $5–8B in 2021–2023.
- Lawsuits & regulators
- Celgene suit (2018) settled for $239M, approved May 2026 → −0.5; CVR holders' suits unresolved → no deduction; the 2004 SEC case and the 2002–2004 shareholder suit are older than 15 years and not counted.
- Related parties
- Related-party transactions limited to routine BlackRock/Vanguard/JPM services on market terms (2026 proxy).
How the score works · checked as of Sep 2026
Bristol Myers Squibb (BMY) earnings: FAQ
How does Bristol Myers Squibb make money?
Bristol Myers Squibb brought in $13.0 billion of revenue in Q2 2026, up 5.7% year over year. The largest source was Growth Portfolio: $7.56 billion, or 58% of the total, followed by Legacy Portfolio ($5.42B, 42%). Net income for the quarter was $3.32 billion, up 153% year over year.
When is BMY's next earnings date?
Bristol Myers Squibb (BMY) is scheduled to report on Oct 29, 2026, before market open.
What time does BMY report earnings?
Bristol Myers Squibb is scheduled to report before market open on Oct 29, 2026. Its last results releases were filed before market open, most recently at 7:05 am ET on Jul 30, 2026.
When did BMY last report earnings?
Bristol Myers Squibb reported Q2 2026 results on Jul 30, 2026.
What is the EPS estimate for BMY's next earnings?
The consensus EPS forecast is $1.68 (9 analysts), vs $1.63 in the same quarter last year.
Where can I find Bristol Myers Squibb's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to BMY's filings; this page breaks the latest report down in a Sankey chart.
What was BMY's net income in Q2 2026?
Bristol Myers Squibb reported net income of $3,317M for Q2 2026 (+153% year over year), under US GAAP.
Does Bristol Myers Squibb pay dividends?
Yes. In 2025, Bristol Myers Squibb paid $5,045M in dividends on its common stock, per its 10-K. Earlier years are in the five-year table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing on 08/25/2026. How we make the breakdowns · Report an error
More reports: CI · Q2 2026 · CVS · Q2 2026 · DHR · Q2 2026 · ELV · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · ISRG · Q2 2026 · JNJ · Q2 2026 · LLY · Q2 2026 · MCK · Q1 FY2027 · all reports